Literature DB >> 24865544

MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.

Muhammad Wasif Saif1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24865544     DOI: 10.6092/1590-8577/2507

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


× No keyword cloud information.
  6 in total

1.  Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.

Authors:  Huang-Chiao Huang; Srivalleesha Mallidi; Joyce Liu; Chun-Te Chiang; Zhiming Mai; Ruth Goldschmidt; Neema Ebrahim-Zadeh; Imran Rizvi; Tayyaba Hasan
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

Review 2.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 3.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.

Authors:  Vladimir P Torchilin
Journal:  Nat Rev Drug Discov       Date:  2014-10-07       Impact factor: 84.694

Review 4.  Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment.

Authors:  H Zare-Zardini; A Amiri; M Shanbedi; A Taheri-Kafrani; Z Sadri; F Ghanizadeh; H Neamatzadeh; R Sheikhpour; F Keyvani Boroujeni; R Masoumi Dehshiri; A Hashemi; M M Aminorroaya; M R Dehgahnzadeh; Sh Shahriari
Journal:  Iran J Ped Hematol Oncol       Date:  2015-12-10

5.  A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.

Authors:  Nai-Jung Chiang; Tsu-Yi Chao; Ruey-Kuen Hsieh; Cheng-Hsu Wang; Yi-Wen Wang; C Grace Yeh; Li-Tzong Chen
Journal:  BMC Cancer       Date:  2016-11-21       Impact factor: 4.430

6.  Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.

Authors:  Barry J Liang; Michael Pigula; Yan Baglo; Daniel Najafali; Tayyaba Hasan; Huang-Chiao Huang
Journal:  J Nanobiotechnology       Date:  2020-01-02       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.